Showing results (11-20 of 40) with videos related to
Sort By:
Pageof 4
European Journal of Medicinal Chemistry|March 28, 2025
Discovery of phenylisoxazolidine analogs targeting receptor interacting protein kinase 1 with anti-inflammatory activityLiangliang Ma, Yonglei Zhang, Zhongwen Luo, et al.International Journal of Biological Macromolecules|August 1, 2020
Paeoniae radix alba polysaccharides obtained via optimized extraction treat experimental autoimmune hepatitis effectivelySiyu Wang, Jiazhi Xu, Changfu Wang, et al.European Journal of Medicinal Chemistry|April 28, 2024
Improving tumor sensitivity by the introduction of an ester chain to triaryl derivatives targeting PD-1/PD-L1Yonglei Zhang, Fucheng Yin, Zhongwen Luo, et al.European Journal of Medicinal Chemistry|March 18, 2025
Discovery of dual CDK4/6 and BRD4 inhibitor as apoptosis and autophagy inducers against NSCLC in vitro and in vivoYonglei Zhang, Zhongwen Luo, Yuhan Jiang, et al.Journal of Medicinal Chemistry|November 22, 2024
Discovery of Dual CDK6/BRD4 Inhibitor Inducing Apoptosis and Increasing the Sensitivity of Ferroptosis in Triple-Negative Breast CancerYonglei Zhang, Long Zheng, Liangliang Ma, et al.European Journal of Medicinal Chemistry|February 21, 2023
Discovery of Sibiriline derivatives as novel receptor-interacting protein kinase 1 inhibitorsNingjie Cui, Shang Li, Yonglei Zhang, et al.Marine Biotechnology (New York, N.Y.)|July 26, 2013
Involvement of JNK in the embryonic development and organogenesis in zebrafishYamei Xiao, Yonghua Zhou, Zhen Xiong, et al.Journal of Medicinal Chemistry|March 5, 2026
Development of Dihydroquinoxalinone-Based Dual CDK6/BET Inhibitors for Triple-Negative Breast Cancer TherapyLong Zheng, Yiwei Zheng, Sijie Wu, et al.Bioorganic & Medicinal Chemistry|June 28, 2023
Design, synthesis and mechanism studies of dual EZH2/BRD4 inhibitors for cancer therapyXinye Chen, Cheng Wang, Dehua Lu, et al.European Journal of Medicinal Chemistry|December 22, 2023
Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapyXinxin Li, Cheng Wang, Shang Li, et al.Pageof 4